-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $90

Benzinga·07/10/2026 12:44:09
Listen to the news
Barclays analyst Eliana Merle maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $115 to $90.